Comparative Pharmacology
Head-to-head clinical analysis: ENTOCORT EC versus PREDNISOLONE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENTOCORT EC versus PREDNISOLONE ACETATE.
ENTOCORT EC vs PREDNISOLONE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Budesonide is a corticosteroid with potent glucocorticoid activity and weak mineralocorticoid activity. It binds to the glucocorticoid receptor, leading to anti-inflammatory effects via inhibition of inflammatory mediators such as cytokines and prostaglandins.
Glucocorticoid receptor agonist; modulates gene expression to inhibit pro-inflammatory cytokines, phospholipase A2, and NF-κB; suppresses immune response and inflammation.
9 mg orally once daily in the morning for up to 8 weeks.
5-60 mg orally once daily or divided every 12-24 hours; dose depends on condition and severity. For acute exacerbations, 200-400 mg intramuscularly once.
None Documented
None Documented
Terminal elimination half-life is approximately 2-3 hours; clinically, the extended intestinal release formulation maintains local activity despite short systemic half-life.
Terminal elimination half-life: 2-4 hours (plasma); biological (tissue) half-life: 18-36 hours due to prolonged glucocorticoid receptor-mediated effects. Half-life prolonged in hepatic disease.
Primarily fecal (60-70%) with minimal renal excretion (<10%); extensively metabolized hepatically, metabolites excreted in bile and feces.
Renal (fraction excreted unchanged: <1%); primarily hepatic metabolism to inactive glucuronide and sulfate conjugates eliminated renally and fecally. After oral administration, 12-15% of dose recovered in bile/feces as metabolites.
Category C
Category D/X
Corticosteroid
Corticosteroid